Robert Lorne Hopfner

Robert Lorne Hopfner (board member) discloses dealings in 4 companies, chiefly Vaxcyte, Inc., Inozyme Pharma, Inc. and Evommune, Inc. Between 16 June 2020 and 12 October 2026, the trades on record add up to 66 filings.

On the open market, the record shows 12 purchases worth €22.3M and 40 sales worth €18.2M. On balance, insiders were net buyers of €4.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 3 option exercises.

A typical purchase (the median) is worth €1.3M. Of 12 purchases, 6 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +25.0%. These figures describe past trades and do not predict future prices.

The newest entry dates from 14 October 2026: an option exercise of €62k, in Rallybio Corp. The most recent open-market purchase was published on 22 December 2025, 306 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.